Clinton Group Inc. raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 249.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,362 shares of the biotechnology company’s stock after purchasing an additional 6,681 shares during the period. Clinton Group Inc.’s holdings in United Therapeutics Corporation were worth $1,215,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. HPM Partners LLC raised its position in shares of United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares in the last quarter. First Allied Advisory Services Inc. raised its position in shares of United Therapeutics Corporation by 0.4% in the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 19 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of United Therapeutics Corporation by 0.3% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after acquiring an additional 40 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of United Therapeutics Corporation by 1.4% in the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 45 shares in the last quarter. Finally, Synovus Financial Corp raised its position in shares of United Therapeutics Corporation by 1.2% in the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after acquiring an additional 69 shares in the last quarter.

United Therapeutics Corporation (NASDAQ UTHR) opened at 121.49 on Thursday. The company’s 50-day moving average price is $124.90 and its 200 day moving average price is $127.07. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89. The stock has a market capitalization of $5.28 billion, a P/E ratio of 14.09 and a beta of 1.49.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. During the same quarter in the prior year, the business earned $4.42 earnings per share. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post $10.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/05/united-therapeutics-corporation-uthr-shares-bought-by-clinton-group-inc.html.

UTHR has been the subject of several recent research reports. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. BidaskClub lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, UBS AG reissued a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation has an average rating of “Hold” and a consensus target price of $132.09.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,236 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $131.62, for a total value of $162,682.32. Following the sale, the chief executive officer now directly owns 1,376 shares in the company, valued at $181,109.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares in the company, valued at $443,111.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,462 shares of company stock worth $2,097,116. 7.80% of the stock is owned by insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.